Compare Abbott Laboratories (ABT) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs United Airlines Holdings Inc — how do they compare? Abbott Laboratories trades at $95.4 (market cap $166.94B), while United Airlines Holdings Inc trades at $125.49 (market cap $41.65B). The key difference: Abbott Laboratories is far larger — about 4× United Airlines Holdings Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals.
| ABT | UAL | |
|---|---|---|
Market Cap | $166.94B | $41.65B |
Sector | Health | Industrials |
52-Week High | $136.62 | $136.11 |
52-Week Low | $82.57 | $80.18 |
Enterprise Value | $193.69B | $58.45B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
United Airlines (UAL) trades at $128.31, down 3.76% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.19 surpassing the $1.08 estimate. Financially, UAL shows robust revenue growth, improving profit margins, and attractive valuation ratios, including a P/E of 11.85 and P/S of 0.72. Recent developments include expansion of Starlink Wi-Fi and new routes, supported by positive sector news on lower fuel costs and stable fares.
The outlook for UAL is positive, driven by earnings momentum, cost tailwinds, and strategic growth initiatives. Investment opportunities include upside to the $160.88 consensus price target and sector recovery. Key risks involve fuel price volatility, competitive pressures, and regulatory changes, which could impact profitability and stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
